Abstract: A diagnostic agent for pancreatic exocrine function comprising a dipeptide represented by the following formula (I): X1—R1—Y1??(I) or a pharmaceutically acceptable salt thereof, wherein X1 is a protecting group, R1 is a phenylalanine, glutamine, valine, tyrosine, methionine, serine or threonine residue, and Y1 is a 13C-labeled alanine molecule optionally having a protecting group.

Abstract: A preparation for the diagnosis of pancreatic exocrine function by determining the amount in which a substance administered to a subject or a degradation product or metabolite thereof migrates into the blood and/or is excreted out of the body, wherein the substance is carried by a carrier and released from the carrier when exposed to the action of a pancreatic exocrine function-related factor.

Abstract: The present invention provides a 13C-labeled oligosaccharide or polysaccharide or a salt thereof excluding U—13C-maltose, 13C-starch, 1-13C-maltotetraose and 1-13C-amylose; a derivative of the 13C-labeled oligosaccharide or polysaccharide or salt thereof; a 13C-labeled inclusion complex or a salt thereof, which comprises a cyclodextrin or a modified derivative thereof as a host molecule; a 13C- or 14C-labeled fluorescein ester compound or a salt thereof; and a diagnostic agents for pancreatic exocrine function comprising these compounds 13C- or 14C-labeled.

Abstract: A preparation for the diagnosis of pancreatic exocrine function by determining the amount in which a substance administered to a subject or a degradation product or metabolite thereof migrates into the blood and/or is excreted out of the body, wherein the substance is carried by a carrier and released from the carrier when exposed to the action of a pancreatic exocrine function-related factor.

Abstract: A diagnostic reagent for use in the evaluation of a pharmacological effect of a medicine containing a pharmaceutical agent including an enzyme, an enzyme inhibitor or a receptor ligand or a prodrug of the pharmaceutical agent is provided. Further, a method of screening pharmaceutical agents each comprising an enzyme, an enzyme inhibitor or a receptor ligand and/or prodrugs of the pharmaceutical agents is provided.

Abstract: A diagnostic agent for pancreatic exocrine function comprising an amino acid or a peptide containing at least one 13C or 14C atom, or a pharmaceutically acceptable salt thereof other than Bz-Tyr-13C-PABA is provided. A 13C- or 14C-labeled compound represented by the following formula (II): X2—R2—Y2—Z1 ??(II) or a salt thereof, wherein X2 is a hydrogen atom or a protecting group, R2 is a peptide of 2 to 5 amino acids, an amino acid or a single bond, Y2 is an amino acid, Z1 is an amino acid optionally having a protecting group, and at least one of the amino acids in R2, Y2 and Z1, or at least one of the protecting groups in X2 and Z1 when the protecting groups contain a carbon atom, is 13C or 14C-labeled.

Abstract: A diagnostic agent for pancreatic exocrine function comprising a dipeptide represented by the following formula (I): X1—R1—Y1??(I) or a pharmaceutically acceptable salt thereof, wherein X1 is a protecting group, R1 is a phenylalanine, glutamine, valine, tyrosine, methionine, serine or threonine residue, and Y1 is a 13C-labeled alanine molecule optionally having a protecting group.

Abstract: A preparation for the diagnosis of pancreatic exocrine function by determining the amount in which a substance administered to a subject or a degradation product or metabolite thereof migrates into the blood and/or is excreted out of the body, wherein the substance is carried by a carrier and released from the carrier when exposed to the action of a pancreatic exocrine function-related factor.

Abstract: The present invention provides a 13C-labeled oligosaccharide or polysaccharide or a salt thereof excluding U-13C-maltose, 13C-starch, 1-13C-maltotetraose and 1-13C-amylose; a derivative of the 13C-labeled oligosaccharide or polysaccharide or salt thereof; a 13C-labeled inclusion complex or a salt thereof, which comprises a cyclodextrin or a modified derivative thereof as a host molecule; a 13C- or 14C-labeled fluorescein ester compound or a salt thereof; and a diagnostic agents for pancreatic exocrine function comprising these compounds 13C- or 14C-labeled.

Abstract: There is disclosed a novel flat heating surface type gas stove which is capable of heating a heating substance across a heat resistance glass at practically applicable heating efficiency, overcoming any inconvenience resulting from the exposure of flame and facilitating the cleaning of the gas stove. This gas stove 10 comprises a heat resistance glass top plate 12 which is disposed over a burner 15, wherein a gas-permeable porous body 40 is disposed below said top plate 12, and a space between said top plate 12 and a surface of said gas-permeable porous body 40 is assigned to a combustion space S. Combustion gas generated is designed to be discharged through said gas-permeable porous body 40. As high-temperature combustion gas passes through said gas-permeable porous body 40, radiant heat B is generated from the surface of said gas-permeable porous body 40. Since the heating substance 4 is heated by both of heat conduction and radiation, high heating efficiency can be achieved.

Abstract: A diagnostic agent for pancreatic exocrine function comprising an amino acid or a peptide containing at least one 13C or 14C atom, or a pharmaceutically acceptable salt thereof other than Bz-Tyr-13C-PABA is provided.

Abstract: There is provided a burner for decomposing nonflammable materials, which is simple in structure and capable of thermally decomposing even a material which is relatively high in thermal decomposition temperature such as CF4 at as high efficiency as 99% or more. This burner comprises a nonflammable material-containing gas-introducing nozzle (40) which is disposed at one end of a cylindrical body (2) so as to enable the nonflammable material-containing gas to be injected around the center along the direction to the central axis (L) of the cylindrical body (2), and a plurality of oxidizing agent/fuel blow-off nozzles are disposed in a manner that these nozzles are positioned on and along circular lines which are coaxial with the central axis (L) of the cylindrical body (2). These blow-off nozzles (50) are inclined in such a degree as to enable flames (f) ejected therefrom to converge onto approximately the same point on the central axis of the cylindrical body (2).

Abstract: There is disclosed a novel flat heating surface type gas stove which is capable of heating a heating substance across a heat resistant glass at a practically applicable heating efficiency, thereby overcoming any inconvenience resulting from the exposure of flame and facilitating the cleaning of the gas stove. This gas stove 10 comprises a heat resistant glass top plate 12 which is disposed over a burner 15, wherein a gas-permeable porous body 40 is disposed below said top plate 12, and a space between said top plate 12 and a surface of said gas-permeable porous body 40 is assigned to a combustion space S. Combustion gas generated is designed to be discharged through said gas-permeable porous body 40. As high-temperature combustion gas passes through said gas-permeable porous body 40, radiant heat B is generated from the surface of said gas-permeable porous body 40. Since the heating substance 4 is heated by both of heat conduction and radiation, high heating efficiency can be achieved.

Abstract: The present invention relates to a diagnostic agent for diabetes, comprising a compound labelled with 13C at least at one specific position selected from the group consisting of the following (a) to (g): (a) galactose, fructose or xylose labelled with 13C at least atone specific position, or a starch composed of glucose units labelled with 13C at least at one specific position; (b) an amino acid labelled with 13C at least at one specific position; (c) lactic acid or citric acid labelled with 13C at least at one specific position; (d) a fatty acid labelled with 13C at least at one specific position; (e) a glyceride labelled with 13C at least at one specific position; (f) glycerol labelled with 13C at least at one specific position; and (g) aminopyrin of which the dimethylamino group at position 4 is labelled with 13C, phenacetin of which the ethoxy group is labelled with 13C at position 1, or methacetin of which the methoxy group is labelled with 13C.

Abstract: There is disclosed a novel flat heating surface type gas stove which is capable of heating a heating substance across a heat resistance glass at practically applicable heating efficiency, overcoming any inconvenience resulting from the exposure of flame and facilitating the cleaning of the gas stove. This gas stove 10 comprises a heat resistance glass top plate 12 which is disposed over a burner 15, wherein a gas-permeable porous body 40 is disposed below said top plate 12, and a space between said top plate 12 and a surface of said gas-permeable porous body 40 is assigned to a combustion space S. Combustion gas generated is designed to be discharged through said gas-permeable porous body 40. As high-temperature combustion gas passes through said gas-permeable porous body 40, radiant heat B is generated from the surface of said gas-permeable porous body 40. Since the heating substance 4 is heated by both of heat conduction and radiation, high heating efficiency can be achieved.

Abstract: The present invention provides a 13C-labeled oligosaccharide or polysaccharide or a salt thereof excluding U-13C-maltose, 13C-starch, 1-13C-maltotetraose and 1-13C-amylose; a derivative of the 13C-labeled oligosaccharide or polysaccharide or salt thereof; a 13C-labeled inclusion complex or a salt thereof, which comprises a cyclodextrin or a modified derivative thereof as a host molecule; a 13C- or 14C-labeled fluorescein ester compound or a salt thereof; and a diagnostic agents for pancreatic exocrine function comprising these compounds 13C- or 14C-labeled.

Abstract: The present invention relates to a diagnostic agent for diabetes, which comprises glucose labelled with 13C at a specific position, or pyruvic acid labelled with 13C at least one specific position. According to the present invention, there is provided a diagnostic agent for diabetes which can be used safely without side effects to give accurate results immediately with less physical pains on the subject. The present diagnostic agent for diabetes can distinguish between healthy persons and patients with diabetes even under the circumstances where the patients are easily missed, and further it can determine the type of diabetes (insulin-dependent type or insulin-independent type).

Abstract: The present invention relates to a reagent for evaluating a hepatic operation, comprising an aromatic amino acid, methionine, alanine, fructose or galactose labelled with 13C at least at one position. According to the present invention, there is provided a reagent for evaluating a hepatic operation, which imposes less physical burden on a subject, can give accurate test results immediately and can be used safely without side effects. The reagent of the invention is useful for measuring the accurate liver excision ratio, liver regeneration/increase ratio or liver weight of a subject after a hepatic operation. With the reagent of the invention, information which is useful for evaluating a hepatic operation and the degree of invasion by the operation and for diagnosis is provided.

Abstract: A method and a device to assess the adequacy of a cathodically protected underground pipeline with consideration of AC corrosion. A steel probe and a CSE are installed near the pipeline at a depth. The steel probe is electrically connected to a pipeline. The measurements of AC probe currents flowing between a steel probe (2) and the pipeline (1) are per-formed simultaneously with those of on-and off-potentials, and DC probe currents.

Abstract: The present invention relates to a diagnostic agent for liver function, comprising a compound labelled with .sup.13 C at least at one specific position selected from the group consisting of the following (a) to (f):(a) galactose, glucose or xylose labelled with .sup.13 C at least at one specific position or a starch composed of glucose units labelled with .sup.13 C at least at one specific position;(b) a polar amino acid, heterocyclic amino acid, isoleucine or valine labelled with .sup.13 C at least at one specific position;(c) a carboxylic acid constituting the glycolytic pathway or the citric acid cycle, labelled with .sup.13 C at least at one specific position;(d) a fatty acid labelled with .sup.13 C at least at one specific position;(e) a glyceride labelled with .sup.13 C at least at one specific position; and(f) glycerol labelled with .sup.13 C at least at one specific position.